ClinicalTrials.gg
CompletedNCT05082545Updated Jun 4, 2024

Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors

A Phase 1 interventional study of SHR-2002 and SHR-1316 in Advanced Malignant Tumors, sponsored by Atridia Pty Ltd.. Completed at 4 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-04.

Sponsored by Atridia Pty Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is Phase 1 study FIH to check "Dose Escalation, Dose expansion and Indication expansion". This study is AUSTRALIA only study.

02

Conditions studied

  • Advanced Malignant Tumors
03

In context

Lead sponsor

Atridia Pty Ltd. is the lead sponsor of 36 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Subjects must meet all the following criteria to be eligible for enrollment into the study:

  1. Ability to understand and voluntarily agrees to participate by giving written for the study;
  2. Male or female aged ≥18 years at the time of signing the ICF;
  3. Histopathologically or documented advanced or and failed or intolerable to previous standard therapy, has no available standard of care therapy or refused standard therapy;
  4. An (ECOG) performance status (PS) score of 0 or 1 (Appendix 2);
  5. Female and male patients of must agree to use highly effective during the study treatment period and within 6 months after the last drug administration.

Subjects who meet any of the following criteria will be excluded from the study:

  1. Patients with known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
  2. Patients with tumor-related pain that cannot be controlled as determined by the investigator.
  3. Systemic anti-tumor therapy within 28 days prior to the first dose of the study treatment
  4. History of diseases, except for Type 1 diabetes (blood glucose can be controlled by insulin therapy)
  5. History of cardiovascular or cerebrovascular diseases within 6 months prior to the first dose of study treatment.
  6. Known history of serious allergic reactions to the investigational product or its main ingredients;
  7. History of immunodeficiency, including positive serum test result and other acquired or congenital immunodeficiency diseases, or history of organ transplantation;
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Dose escalation:SHR-2002+SHR-1316

    SHR-2002 +SHR-1316 C1D1 SHR-2002,C1D22 SHR-2002+SHR-1316, C2 SHR-2002+SHR-1316

    Drug: SHR-2002 and SHR-1316

  • Experimental
    Dose expansion stage: SHR-2002+SHR-1316

    Dose expansion of SHR-2002 will be decided after finishing few cohorts in Dose escalation part.

    Drug: SHR-2002 and SHR-1316

  • Experimental
    Indication expansion stage:SHR-2002+SHR-1316

    Indication expansion of SHR-2002 will be decided after finishing few cohorts in Dose expansion part.

    Drug: SHR-2002 and SHR-1316

Interventions

  • DrugSHR-2002 and SHR-1316

    Drug page: Adebrelimab

    Cohort study

06

What researchers measure

Primary outcomes

  1. Adverse events

    Number of subjects with adverse events (AEs)

    Time frame: Screening up to study completion, an average of 2 years

  2. Number of participants experiencing Dose-Limiting Toxicities (DLTs)

    According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v.5.0)

    Time frame: Up to 42 days

Secondary outcomes

  1. PK of SHR-2002 + SHR-1316

    To check Maximum concentration (Cmax)

    Time frame: Before and after SHR-2002 and SHR-1316 infusion throughout the study, an average of 2 years

  2. PK of SHR-2002 + SHR-1316

    To check AUC last

    Time frame: Before and after SHR-2002 and SHR-1316 infusion throughout the study, an average of 2 years

  3. Immunogenicity of SHR-2002 + SHR-1316

    ADA of SHR-2002 + SHR-1316

    Time frame: Before and after SHR-2002 and SHR-1316 infusion throughout the study, an average of 2 years

07

Study locations

4 sites
  • Icon Cancer Centre
    Brisbane, Queensland 4101, Australia
  • Linear clinical research
    Perth, Western Australia 6009, Australia
  • Scientia Clinical research
    Sydney, 2031, Australia
  • Liverpool Hospital
    Sydney, 2170, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Jul 2023, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2021
First posted
Oct 19, 2021
StartActual
Nov 23, 2021
Primary completionActual
Jul 17, 2023
CompletionActual
Feb 12, 2024
Last update
Jun 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05082545
Lead sponsor
Atridia Pty Ltd.
Responsible party
Sponsor
First posted
Oct 19, 2021
Start date
Nov 23, 2021
Primary completion
Jul 17, 2023
Completion
Feb 12, 2024
Last update
Jun 4, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adebrelimab

Start the discussion